Why Amarin Is Tanking Post-Approval


Investors in Amarin enjoyed the run-up to Vascepa's approval more than the days that followed. Shares were down an additional 10% yesterday as insider selling had investors spooked ahead of the FDA's new chemical entity ruling for the company's lead drug. Is this a market overreaction, or should investors be concerned about the transaction? Watch and find out.

Many investors are attracted to Amarin and biotechs like it since they hold the allure of substantial short-term gains. But there is more than one approach to building long-term wealth and retiring well. In our free report, "3 Stocks That Will Help You Retire Rich," we reveal some stocks that could help you as well as some winning wealth-building strategies. Click here to keep reading.

The article Why Amarin Is Tanking Post-Approval originally appeared on Fool.com.

David Williamson owns shares of Amarin, but he holds no other position in any company mentioned. Click here to see his holdings and a short bio. The Motley Fool has a disclosure policy. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. Try any of our Foolish newsletter services free for 30 days.

Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.